Hormone Optimization & Testing

Dallas Longevity Center offers comprehensive hormone testing and optimization for men and women, assessing sex hormones, thyroid function, adrenal markers, and growth factors through advanced laboratory analysis. A functional medicine physician reviews results and designs a personalised hormone optimization protocol — which may include bioidentical hormone therapy, peptide support, nutritional interventions, or lifestyle modifications — based on each patient's labs, symptoms, and health goals.

Hormone optimization at Dallas Longevity Center begins with a comprehensive lab panel rather than symptom-only assessment. The clinic measures the full hormonal picture: for men, this includes total and free testosterone, SHBG, oestradiol, DHT, LH, FSH, DHEA-S, cortisol AM, and IGF-1; for women, the panel adds progesterone, full thyroid including reverse T3 and thyroid antibodies, and — depending on menopausal status — a broader reproductive hormone profile. This breadth of testing allows the practitioner to identify not just low testosterone or hypothyroidism in isolation, but the interplay between axes — for example, elevated cortisol suppressing gonadal hormone production, or low DHEA-S compromising energy and immune resilience independently of sex hormone levels. Functional medicine practitioners at the clinic are trained to interpret hormone data through an optimization lens rather than a reference-range-only framework. A testosterone level of 380 ng/dL may be within the laboratory reference range but substantially suboptimal for a 42-year-old male patient presenting with fatigue and reduced exercise capacity. The clinical conversation centers on where the patient wants to be, not just whether they clear the disease threshold. Where bioidentical hormone replacement therapy (BHRT) is indicated, the clinic designs individualized protocols using compounded bioidentical formulations — topical gels, injectable testosterone cypionate, or pellet insertion depending on patient preference and clinical profile. Monitoring follow-up labs are scheduled at 6–8 weeks post-initiation and quarterly thereafter to ensure levels remain in optimal ranges with appropriate adjustments. Peptide therapy — including Sermorelin, BPC-157, and Ipamorelin — is offered as a complementary protocol for patients seeking growth hormone axis support or tissue recovery enhancement without exogenous GH administration. For DFW men and women experiencing hormonal decline symptoms — fatigue, cognitive fog, body composition changes, low libido — the clinic provides a data-driven alternative to symptom-only prescribing.